Overview

Treatment of AA Amyloidosis

Status:
COMPLETED
Trial end date:
2024-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.
Phase:
PHASE1
Details
Lead Sponsor:
Nelson Leung, MD